EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and efficacy of neoadjuvant cisplatin + S-1 combined with radiation therapy for locally advanced non-small cell lung cancer

Takashi Karashima, Shinkichi Takamori, Miyuki Abe, Yohei Takumi, Atsushi Osoegawa, Kenji Sugio

Surgery Today · 2025

DOI: 10.1007/s00595-025-03019-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery Today, 2025. Verfasst von Takashi Karashima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-Machi, Yufu, 879-5593, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cisplatin, Tegafur, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oita University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess the safety and efficacy of neoadjuvant chemoradiotherapy with cisplatin plus S-1 for advanced non-small cell lung cancer (NSCLC), with a focus on real-world outcomes.

Methods

This retrospective study analyzed 32 patients with stage II-III NSCLC eligible for resection, who received preoperative induction therapy between January 2012 and December 2022. Specifically, 20 patients received cisplatin, S-1, and radiation therapy.

Results

Among the 32 patients who received induction therapy, the objective response rate (ORR) was 56.2%, and surgical resection was feasible in 29 patients (90.6%). The 5 year recurrence-free survival (RFS) rate was 76.4%, and the 3- and 5 year overall survival (OS) rates were 86.2% and 82.3%, respectively. In the cisplatin + S-1 + radiation therapy group (n = 20), the ORR was 65.0%, and surgical resection was feasible in 17 patients (85.0%). The 3-year RFS and OS rates were 78.3% and 83.8%, respectively. Ef. 3 (complete pathological response) was observed in 3 patients (10.3%). No recurrences occurred in the non-adenocarcinoma subgroup (n = 6), indicating better outcomes relative to the adenocarcinoma group (5-year RFS, 100% vs. 61.4%; p = 0.07).

Conclusions

Induction therapy, particularly with cisplatin + S-1 + radiation was associated with promising RFS and OS in locally advanced NSCLC, with favorable tolerability and effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCisplatinTegafurLung NeoplasmsOxonic AcidNeoadjuvant TherapyChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleDrug CombinationsMiddle AgedAgedRetrospective StudiesTreatment OutcomeSurvival RateNeoplasm StagingAdultSafety

Stichwörter der Autor:innen

ChemoradiotherapyCisplatinNeoadjuvant therapyNon-small cell lung cancerRadiationS-1

Substanzen

CisplatinTegafurS 1 (combination)Oxonic AcidDrug Combinations

Autor:innen und Institutionen

  • Department of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-Machi, Yufu, 879-5593, Japan.
  • Department of Thoracic and Breast Surgery, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-Machi, Yufu, 879-5593, Japan. osoegawa-ths@oita-u.ac.jp.

Förderung

  • Oita University

Zitieren

APA

Karashima, T., Takamori, S., Abe, M., Takumi, Y., Osoegawa, A., & Sugio, K. (2025). Safety and efficacy of neoadjuvant cisplatin + S-1 combined with radiation therapy for locally advanced non-small cell lung cancer. Surgery Today. https://doi.org/10.1007/s00595-025-03019-9

Vancouver

Karashima T, Takamori S, Abe M, Takumi Y, Osoegawa A, Sugio K. Safety and efficacy of neoadjuvant cisplatin + S-1 combined with radiation therapy for locally advanced non-small cell lung cancer. Surgery Today. 2025. doi:10.1007/s00595-025-03019-9

BibTeX
@article{Karashima2025,
  author = {Karashima, Takashi and Takamori, Shinkichi and Abe, Miyuki and Takumi, Yohei and Osoegawa, Atsushi and Sugio, Kenji},
  title = {Safety and efficacy of neoadjuvant cisplatin + S-1 combined with radiation therapy for locally advanced non-small cell lung cancer},
  journal = {Surgery Today},
  year = {2025},
  doi = {10.1007/s00595-025-03019-9}
}
Kostenlos starten →